Dextrin

Summary

Dextrin (CHEMBL2108197) is a phase-3 clinical-stage unknown; indicated across 5 conditions including cardiovascular disorder and small cell lung carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 5 conditions
• Clinical trials: 7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108197
Name	Dextrin
Type	Unknown
Max phase	3

Also known as: Dextrin, DEXTRIN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	2	MONDO:0004995	EFO:0000319
small cell lung carcinoma	2	MONDO:0008433	EFO:0000702
autoimmune thrombocytopenic purpura	1	MONDO:0008558	EFO:0007160
HIV infectious disease	1	MONDO:0005109	EFO:0000764

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
Not specified	5
PHASE1/PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06827002	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Effect of Aqueous Extracts of Cissus Quadrangularis and Dichrostachys Glomerata on GLP-1 Concentration and DPP-4 Activity in Overweight and Obese Adults
NCT00004987	PHASE1	UNKNOWN	Treatment of Advanced AIDS Patients With Dextrin Sulfate
NCT06433037	Not specified	ACTIVE_NOT_RECRUITING	Gut-brain Health Effects of PREbiotics in Older Adults With Suspected COgnitive DEcline
NCT03303729	Not specified	COMPLETED	Influence of Carbohydrate on Amino Acid Absorption From Dietary Protein (ICADP)
NCT06126094	Not specified	UNKNOWN	Benefits of Alcoholic Hangover Medicine
NCT06224803	Not specified	COMPLETED	Evaluation of Effects of Dibifree® on Regulation of Blood Sugar and HbA1c in Patients With Type II Diabetes
NCT06883292	Not specified	COMPLETED	The Effects of Tyrosol and Creatine on Endurance, Strength, and Fatigue Resistance in Healthy Adults

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).